Highlights NextCell Pharma AB

Equities

NXTCL

SE0009723125

Market Closed - Nasdaq Stockholm Other stock markets 09:57:01 2024-05-21 am EDT			5-day change	1st Jan Change
1.35 ^SEK	+4.65%		+10.20%	-48.67%

Apr. 25	NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
Apr. 22	NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 25	CI
NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue	Apr. 22	CI
The Swedish Medical Products Agency Approves Subgroup Analysis in NextCell Pharma AB's ProTrans-Young study	Mar. 27	CI
NextCell Pharma AB Establishes QVance to Meet the Nordic's Need for Quality Analytics	Mar. 14	CI
NextCell Pharma AB Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 25	CI
Nextcell Pharma Announces Updates Regarding Nextcell's Clinical Trials with Protrans	Jan. 24	CI
NextCell Pharma AB Announces Repeated Treatment with ProTrans Is Immunologically Safe	Nov. 06	CI
NextCell Pharma AB Reports Earnings Results for the Full Year Ended August 31, 2023	23-10-26	CI
NextCell Pharma AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	23-10-26	CI
Nextcell Pharma, Lino Signs Distribution Deal in Sweden	23-10-10	MT
Nextcell Pharma AB Signs an Agreement for A New Tissue Product with Linio	23-10-10	CI
NextCell Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-07-27	CI
NextCell Pharma AB Announces Treatment Start of Severe Pneumonia with High Dose of ProTrans	23-07-05	CI
NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-27	CI
FDA Approves a Product of Multiplied Stem Cells from Umbilical Cord Blood of NextCell Pharma AB	23-04-26	CI
Nextcell Pharma AB Publishes the Phase I/II Clinical Trial in Type I Diabetes Accepted	23-03-28	CI
NextCell Pharma AB Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-26	CI
NextCell Pharma AB Announces First Pediatric Patients Treated with ProTrans in Type-1 Diabetes Phase II Study	22-12-21	CI
NextCell Pharma AB Reports Earnings Results for the Full Year Ended August 31, 2022	22-11-03	CI
NextCell Pharma Receives OK For Phase II Study On Diabetes Treatment In Children, Adolescents	22-10-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NextCell Pharma AB

Equities

NXTCL

SE0009723125

Highlights

Filters